Theisen M. Somewhat unique to plant-produced pharmaceuticals are potential effects on non-target species such as butterflies, honeybee, and other wildlife at or near the growing sites.
Through genetic engineering, plants can now be used to produce pharmacologically active proteins, including mammalian antibodies, blood product substitutes, vaccines, hormones, cytokines, and a variety of other therapeutic agents. Table 4.
Split View Views. It is also necessary to decide which plant species to transform for production of a specific pharmaceutical product. Relevant antigens are naturally stored in plant tissue, and oral vaccines can be effectively administered directly in the food product in which they are grown, eliminating purification costs.
Growing plants for pharmaceutical production vs. HighTech Business Decisions Report. Transgen Res.
Future directions. While glycosylation sequences are poorly immunogenic and hence unlikely to precipitate immunological adverse reactions, 8 the presence of mammalian glycosylation sequences not required for therapeutic function may only serve to produce undesired complement- or cell-mediated side effects.
Monoclonal antibodies mAbs have been critical both for the development of biotechnology itself and as products for both therapeutic and diagnostic purposes. One such device uses a glucose sensor implanted into the patient. Dr Thomas has served from time to time as a consultant to Monsanto in the areas of plant biotechnology and food safety assessment, and did receive remuneration for his efforts in preparing this manuscript.
It's potentially troublesome to think of these genes falling into the food supply, like StarLink," she says.
Unfortunately, our capacity to produce these proteins in the quantities needed is expected to fall far short of demand by the end of the current decade. The relatively small scale and favourable economics of biopharmaceutical operations allows the placement of field operations in geopolitical locations selected for optimal security, with subsequent shipping of raw or processed materials.
Thomas; Biopharmaceuticals derived from genetically modified plants, QJM: PB, particle bombardment. Today Genentech is a purely biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals produced by recombinant DNA technology for significant unmet medical needs. There are, however, some limitations associated with the use of transgenic plants for vaccine production.
Maier, professor of agricultural and biological engineering at Purdue University released a fact sheet, stating, "the fact that transgenic grains and oilseeds for use as pharmaceutical drug carriers and industrial chemicals may be making their way into a field near your farm, grain elevator, feed mill or processing plant should be a concern," especially in light of the Starlink corn contamination debacle in 2000.
Maier, Fehr, and the activists are concerned that pollen from these novel GM corn varieties will cross-pollinate with conventional and food corn varieties, thus causing another, and possibly even worse, "Starlink" type problem.
The advantages of recombinant plant DNA technology for the production of antibodies, vaccines, other pharmaceuticals, and even high-volume plasma proteins are becoming increasingly apparent. Transgenic plants have the added safety feature of freedom from human or animal pathogens.